Frequency of thromboembolic complications in patients with lung cancer;Häufigkeit thromboembolischer Komplikationen bei Patienten mit Lungenkarzinom

Pneumologie

Volumn 67, Issue 8, 2013, Pages 442-447

  Crolow, C ^a   Samulowski, M ^a   Blum, T ^a   Kollmeier, J ^a   Schonfeld N ^a   Bittner, R C ^a   Behr, J ^b   Bauer, T T ^a   Gruning W ^c  

^a HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c HELIOS KLINIKEN SCHWERIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM;

ARTERIAL THROMBOEMBOLISM; ARTICLE; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CORONARY ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HISTOLOGY; HUMAN; ISCHEMIA; LIMB ISCHEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MESENTERIC ARTERY OCCLUSION; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RENAL ARTERY THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; CAUSALITY; COMORBIDITY; FEMALE; GERMANY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; THROMBOEMBOLISM;

EID: 84881124903     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0033-1344341     Document Type: Article

References (34)

1. Heit J. A., Silverstein M. D., Mohr D. N. et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med: 2000; 160 809 815 (Pubitemid 30165241)
2. Chew H. K., Wun T., Harvey D. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med: 2006; 166 458 64
3. Blom J., Vanderschoot J., Oostindiër M. et al. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost: 2006; 4 529 535
4. Silverstein M. D., Heit J. A., Mohr D. N. et al. Trends in the Incidence of Deep Vein Thrombosis and Pulmonary Embolism. Arch Intern Med: 1998; 158 585 593 (Pubitemid 28144815)
5. Lee A. YY, Levine M. N. Venous thromboembolism and cancer: risks and outcomes. Circulation: 2003; 107 I17 21 (Pubitemid 41289267)
6. Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale De l'Hotel-Dieu De Paris. 03 Vol. 2nd Ed.: 1865; 654 712
7. Shen V. S., Pollak E. W. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? The Southern Medical Journal: 1980; 73 841 843 (Pubitemid 11000639)
8. Hettiarachchi R. J., Lok J., Prins M. H. et al. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer: 1998; 83 180 185 (Pubitemid 28299645)
9. Hach-Wunderle V., Schellong S., Encke A. NT. AWMF online Diagnostik und Therapie der Venenthrombose und der Lungenembolie. AWMF Online: 2010
10. Sorensen H. T., Mellemkjaer L., Steffensen F. H. et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med: 1998; 338 206 207
11. Levitan N., Dowlati A., Remick S. C. et al. Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy. Medicine: 1999; 78 285 291 (Pubitemid 29439263)
12. Khorana A. A., Francis C. W., Culakova E. et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer: 2005; 104 2822 2829 (Pubitemid 41798294)
13. Barni S., Labianca R., Agnelli G. et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med: 2011; 9 179
14. Lee A. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treatment Reviews: 2002; 7372 137 140
15. Blom J. W., Osanto S., Rosendaal F. R. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost: 2004; 2 1760 1765 (Pubitemid 40192717)
16. Moore R. A., Adel N., Riedel E. et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol: 2011; 29 3466 3473
17. Roger V. L., Go A. S., Lloyd-Jones D. M. et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation: 2012; 125 e2 e220
18. Wiesner G., Grimm J., Bittner E. et al. Zum Herzinfarktgeschehen in der Bundesrepublik Deutschland: Prävalenz, Inzidenz, Trend, Ost-West-Vergleich. Gesundheitswesen: 1999; 61 72 78
19. Khorana A. A., Francis C. W., Culakova E. et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol: 2006; 24 484 490 (Pubitemid 46630468)
20. Goldstein L. B., Bushnell C. D., Adams R. J. et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke: 2011; 42 517 584
21. Diener H. C. Primär- und Sekundärprävention der zerebralen Ischämie. In: Leitlinien Für Diagnostik und Therapie in der Neurologie. 4. überarbeitete Auflage. Stuttgart Georg Thieme Verlag Stuttgart: 2008; 654 ff
22. Camm a. J., Kirchhof P., Lip G. YH et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal: 2010; 31 2369 2429
23. Bona R., Hickey A., Wallace D. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am J Clin Oncol: 2000; 23 71 73 (Pubitemid 30407365)
24. Hutten B. BA, Prins M. H., Gent M. et al. Incidence of Recurrent Thromboembolic and Bleeding Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis. J Clin Oncol: 2000; 18 3078 3083
25. Pabinger I., Alt-Epping B., Biasutti F. Venöse Thrombembolien bei Tumorpatienten. Hämostaseologie: 2011; 281 290
26. Guyatt G. H., Akl E. A., Crowther M. et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 7S 47S
27. Lyman G. H., Khorana A. A., Kuderer N. M. et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol: 2013; 31 1 17
28. Mandal M., Labianca R. Venous thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management: 2010; 2 117 119
29. Hirsh J., Fuster V., Ansell J. et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation: 2003; 107 1692 1711 (Pubitemid 36397341)
30. Gitter M. J., Jaeger T. M., Petterson T. M. et al. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clinic Proceedings. Mayo Clinic: 1995; 70 725 733
31. White R., Beyth R., Zhou H. et al. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med: 1999; 107 414 424 (Pubitemid 29528329)
32. Agnelli G., George D. J., Kakkar A. K. et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med: 2012; 366 601 609
33. Levine M. N., Gu C., Liebman H. A. et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost: 2012; 10 807 814
34. Agnelli G., Buller H., Cohen A. Apixaban for extended treatment of venous thromboembolism. N Engl J Med: 2013; 368 699 708